Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SILO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSilo Pharma acquires QwikAgents software platform for 2.1M shares in off-strategy deal
Filed April 2, 2026 · Period ending March 30, 2026 · ~1 min read
Key Changes
-
high
Company acquired QwikAgents web application software and three domain names from Many Ads Inc. for 2.1 million common shares, diluting existing shareholders while preserving cash. The acquisition appears unrelated to Silo's pharmaceutical business.
Item 1.01 verify on EDGAR → -
high
The 2.1M share issuance was a private placement under Section 4(a)(2) exemption, meaning shares are restricted and not immediately tradable. Actual dollar value of consideration depends on stock price at July 2025 issuance date.
Item 3.02 verify on EDGAR → -
medium
Seller provided standard indemnification covering misrepresentations, IP infringement claims, and misconduct. This offers some protection if third parties claim ownership of the software or if undisclosed liabilities emerge.
Item 1.01 verify on EDGAR →
Summary
Silo Pharma, a pharmaceutical company, made an unusual strategic pivot by acquiring QwikAgents, a web-based software application, along with related domain names. The company paid entirely in equity—2.1 million common shares—which dilutes existing shareholders but avoids cash outflow. The filing provides no explanation for why a pharma company is acquiring software assets, raising questions about strategic direction and management focus.
Retail investors should note the share dilution and the apparent departure from the company's core pharmaceutical business. The acquisition occurred in July 2025 but is only being disclosed now in March 2026, a nine-month delay that warrants scrutiny. Watch for management commentary explaining the strategic rationale and whether QwikAgents generates meaningful revenue or represents further diversification away from drug development.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On July 29, 2025, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Many Ads Inc. (the “Seller”). Pursuant to the Agreement, the Seller agreed to sell, and the Company agreed to purchase, certain software of the web-based application currently marketed as “QwikAgents” and the domain names qwikagents.com, qwikagents.ai, and qwikagents.co (the “Purchased Assets”).
The company entered into an asset purchase agreement to acquire QwikAgents, a web-based application software platform, along with three related domain names. This represents a strategic acquisition of technology assets outside the company's traditional pharmaceutical focus.
Added in current filing · verify on EDGAR →
In consideration for the Purchased Assets, the Company issued to the Seller, 2,100,000 shares of its common stock, par value $0.0001 per share (the “Shares”).
The company paid for the acquisition entirely with equity, issuing 2.1 million shares of common stock to the seller. This dilutes existing shareholders but preserves cash, and the actual dollar value depends on the stock price at issuance.
Event · Item 3.02 — Unregistered Sales of Equity Securities
Silo Pharma issued unregistered equity securities in a private transaction under Section 4(a)(2) exemption.
Added in current filing · verify on EDGAR →
The offer and sale to the Seller of the Shares was made in reliance upon Section 4(a) (2) under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
The company sold shares to a seller in a private placement without registering them with the SEC, using the Section 4(a)(2) exemption for transactions not involving a public offering. The filing references Item 1.01 for additional details but that section is not included in the provided text, so specifics about the number of shares, price, and buyer identity are not disclosed here.
Event · Item 9.01 — Financial Statements and Exhibits
Silo Pharma entered into an Asset Purchase Agreement with Many Ads Inc. on March 31, 2026.
Added in current filing · verify on EDGAR →
Asset Purchase Agreement, dated March 31, 2026, between the Company and Many Ads Inc..
Silo Pharma disclosed entering into an Asset Purchase Agreement with Many Ads Inc. on March 31, 2026. The 8-K does not provide details about which assets were purchased, the purchase price, or the strategic rationale. The full agreement is filed as Exhibit 10.1.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify